PDF-Commissioning Policy

PDF-Commissioning Policy thumbnail
OFFICIAL 1 Clinical Tocilizumab for the treatment of adult onset Stills disease refractory to second line therapy adults 21 08 01P URN 1609 First p ublished June 20 18 Updated

Download Presentation

"Commissioning Policy" is the property of its rightful owner. Permission is granted to download and print materials on this website for personal, non-commercial use only, provided you retain all copyright notices. By downloading content from our website, you accept the terms of this agreement.

Presentation Transcript

Transcript not available.

Related Topics